Ensemble develops Ensemblins to treat diseases by addressing drug targets that are currently inaccessible with small molecule drugs.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: Cambridge
State: Massachusetts
Zip:
Country: United States
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2004 | Series A | 3 | $15M |
ARCH Venture Partners Flagship Pioneering Oxford Bioscience Partners ARCH Venture Partners Flagship Pioneering Oxford Bioscience Partners |
11/2007 | Series B | 7 | $15M |
180 Degree Capital Aeneas Ventures ARCH Venture Partners Boston University Technology Development Fund CMEA Ventures Flagship Pioneering Oxford Bioscience Partners 180 Degree Capital Aeneas Ventures ARCH Venture Partners Boston University Technology Development Fund CMEA Ventures Flagship Pioneering Oxford Bioscience Partners |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|